NYC Healthcare News

Researchers commence Phase 2 research study to test CERE-110 for AD

August 18, 2015

A Phase 1 study was conducted at University of California San Diego.  The 10 subjects underwent cognitive testing, measures of activities of daily living, and MRI and PET (positron emission tomography) scans.  Researchers observed increases in brain metabolism in several cortical regions of the brain at six months and 12 months in some of the participants, as compared to other severity-matched individuals with AD, suggesting a potential reversal of patterns typically observed in AD.

The Phase 2 Clinical Study

In this blinded study, all eligible participants will be randomized by chance to one of two treatment groups:  half will receive CERE-110 and half will receive placebo (inactive drug).  Once the study is completed, and if the results are promising, participants in the placebo group will be eligible to receive CERE-110.  

The NGF study is being conducted by the Alzheimer's Disease Cooperative Study (ADCS), a nationwide consortium of research centers and clinics supported by the National Institute on Aging (NIA), part of the National Institutes of Health, and coordinated by the University of California San Diego.  Ceregene, Inc., the study sponsor, is a San Diego-based biotechnology company focused on the delivery of nervous system growth factors via gene transfer for the treatment of neurodegenerative disorders.  Ceregene is providing CERE-110 for the study.  

SOURCE Banner Sun Health Research Institute